Dr. Emanuel Gasser is a Lecturer at the Department of Health Sciences and Technology at ETH Zürich. He leads the Laboratory of Nutrition and Metabolic Epigenetics within the Institute of Food, Nutrition and Health. His research focuses on understanding how metabolic states are influenced by epigenetic mechanisms, particularly in obesity, diabetes, and lipid metabolism. Gasser’s work bridges nutritional science with molecular biology to explore interventions targeting metabolic disorders. Key research areas include the role of FGF1 in metabolic regulation, epigenetic memory in adipose tissue, and the development of immune-evasive islet organoids for diabetes treatment. His studies often integrate stem cell technologies, epigenetic profiling, and metabolic disease modeling. Publications highlight advancements in FGF1 signaling pathways, mechanisms of metabolic memory post-weight loss, and innovative approaches to overcoming immune rejection in islet transplantation. Gasser collaborates broadly in metabolic epigenetics and translational medicine, contributing to both fundamental science and clinical applications.
Prof. Dr. Ferdinand von Meyenn is an Assistant Professor at the Department of Health Sciences and Technology at ETH Zürich. He leads the Laboratory of Nutrition and Metabolic Epigenetics, focusing on the interplay between nutrition, metabolism, and epigenetic regulation in health and disease. His research spans topics such as epigenetic memory in adipose tissue, stem cell reprogramming, and the metabolic consequences of obesity. Key projects include developing novel iron delivery platforms using oat protein nanofibrils and investigating the role of histone modifications in aging mechanisms. His work integrates multi-omics approaches, including spatial transcriptomics and single-cell analysis, to uncover how environmental factors like diet and metabolic stress influence epigenetic landscapes. Recent studies highlight his team’s contributions to understanding how mitochondrial dysfunction contributes to neurological disorders and how microalgae can address micronutrient deficiencies sustainably. Publications emphasize translational applications, such as reversing beta-cell dysfunction in type 2 diabetes and creating age predictors using chromatin accessibility (ATAC-clock). Collaborations with clinical microbiology units suggest interdisciplinary engagement in translational research.
Stefan Amisten serves as a Research Fellow in Islet Cell Physiology at Lund University's Faculty of Medicine , focusing on molecular mechanisms underlying pancreatic islet function and diabetes pathophysiology. His work bridges basic molecular biology with clinical endocrinology to identify novel therapeutic targets. His research expertise spans critical domains: Molecular Endocrinology - GPCR signaling networks in human/mouse islets Signal Transduction - cAMP dynamics in insulin secretion Diabetes Mechanisms - UDP-glucose metabolism and beta-cell dysfunction Receptor Pharmacology - Imidazoline/eicosanoid receptor systems Cellular Repair Processes - DNA repair factors in angiogenesis His fingerprint analysis reveals dominant activity in GPCR research (100% Medicine/Dentistry), cAMP signaling (79%), and pancreatic islet biology (55%). Publication trends (2017-2025) show escalating focus on receptor expressome mapping and translational diabetes research. His 2017 Scientific Reports paper (65 citations) established foundational GPCR expression atlases, while recent work explores ku80's role in vascular biology. Publications appear in high-impact journals including Cellular and Molecular Life Sciences and The Journal of Biological Chemistry , with strong social media engagement (91+ shares). No scientific awards were documented in the profile. Information regarding student supervision, grant funding, or laboratory infrastructure was not provided in available materials.
Louise Torp Dalgaard is a Professor of Medical Biology at Roskilde University's Department of Science and Environment. Her research focuses on diabetes mellitus, pancreatic β-cell dysfunction, and microRNA roles in metabolism. She leads projects on biomarker development for metabolic disorders and studies microRNA regulation in mitochondria and islet cells. Education: PhD in Biomedicine (2001, University of Copenhagen), MSc in Human Biology (1998), and international studies in biochemistry (1992). Professional experience includes postdoctoral work at Harvard Medical School (2001–2003) and roles as Head of Studies in Medical Biology (2018–2020). Research interests span β-cell failure mechanisms in type 2 diabetes, microRNA roles in mitochondrial function, and biomarker applications for diabetic complications. Key projects include profiling miRNAs in PCOS, obesity, and wound healing. Her lab uses molecular biology tools (Q-PCR, CRISPR) and collaborates with clinical partners. Awards include the Poul and Erna Sehested-Hansen Foundation Honor Bursary (2013). She chairs international conferences and serves on ethics committees (e.g., Genome Center Denmark). Notable grants exceed 16 million DKK, supporting postdocs and collaborations on diabetic wound healing and mitochondrial biology. Key Projects: MicroRNA biomarkers in diabetes, mitochondrial miRNA mapping, β-cell regeneration Administrative Roles: Danish Diabetes Academy committees, Roskilde University Education Committee
Professor Andreas Linkermann holds the Chair of Nephrology at Heidelberg University's Mannheim Medical Faculty and directs the Fifth Department of Medicine at Mannheim University Hospital. His work integrates clinical care, research, and teaching across nephrology, transplantation medicine, endocrinology, and pulmonology. Research focuses on regulated cell death mechanisms (ferroptosis, necroptosis) in kidney diseases, acute organ injury, and transplant preservation. Key contributions include elucidating gasdermin D's role in immunothrombosis and defining ferroptosis pathways in metabolic and cardiovascular disorders. He leads translational projects on biomarkers for normothermic organ perfusion and sex-based differences in acute kidney injury. As a clinical leader, he oversees multidisciplinary teams advancing precision medicine approaches in renal and metabolic diseases. Research interests span cell death immunogenicity, STING signaling in inflammation, and therapeutic targeting of lipid peroxidation. His work bridges basic science and clinical applications, with recent emphasis on ferroptosis modulation in diabetes, ischemia-reperfusion injury, and cancer cell vulnerability. He collaborates with the Mannheim Medical Technology Campus and contributes to Baden-Württemberg's healthcare innovation initiatives.
Thomas Wieland is a Professor and Chair of Experimental Pharmacology at the Medical Faculty Mannheim, Heidelberg University. His research focuses on cardiovascular signaling pathways, particularly the roles of nucleoside diphosphate kinases (NDPK) and G protein-mediated signaling in diseases like diabetic retinopathy and hypertension. He investigates endothelial dysfunction, vascular biology, and the molecular mechanisms underlying cardiovascular pathologies. Key research interests include the regulation of Rho GTPases, endothelial adherens junctions, and the interplay between metabolic pathways and vascular damage. His work utilizes mouse models, zebrafish embryos, and cultured endothelial cells to study disease mechanisms and identify therapeutic targets. Notably, his group has characterized NDPK B's role in caveolae formation, angiogenesis modulation, and diabetic complications. Recent studies explore how NDPK isoforms influence tumor metastasis, inflammatory responses, and cardiac remodeling. His findings contribute to understanding how histidine phosphorylation and G protein signaling dysregulation drive vascular pathologies. While no specific grants are listed, his publications highlight collaborative projects involving cardiovascular, metabolic, and oncological research. Labs/Teams: Experimental Pharmacology group at Heidelberg University, collaborating with departments in cardiology, molecular biology, and clinical medicine.
Jasenka Guduric-Fuchs is a Research Fellow at the Wellcome Wolfson Institute for Experimental Medicine, Queen's University Belfast. Her research focuses on microRNA regulation in endothelial cells, diabetic retinopathy pathogenesis, and vascular regeneration therapies. Key investigations include endothelial progenitor dysfunction in diabetes, epigenetic dysregulation in hyperglycemia, and pentraxin-mediated retinal inflammation. Develops stem cell-based approaches for ischemic retinopathies and studies extracellular vesicle signaling in age-related macular degeneration. Publications emphasize molecular mechanisms of vascular aging, microRNA control of angiogenesis, and translational applications for ocular diseases. Recent work identifies novel senescence signatures and explores NOX4 signaling restoration for diabetic vascular repair. Collaborates internationally on retinal vascular biology projects. Research contributes to therapeutic development for diabetic complications and retinal degenerative diseases.
Scott B. Selleck is a Professor in the Department of Biochemistry and Molecular Biology at The Pennsylvania State University. He previously served as Department Head (2009–2017) and held the Martin Lenz Harrison Endowed Chair at the University of Minnesota (2002–2009). His research focuses on signaling networks in neurodevelopment and neurodegenerative diseases, particularly Alzheimer’s and Parkinson’s, with a focus on heparan sulfate proteoglycans’ roles in autophagy and stress responses. Education: Bachelor’s in Zoology, University of Washington MD and PhD, Washington University School of Medicine Postdoctoral Fellowships at MIT and Brandeis University Research Interests: Dr. Selleck’s work explores how heparan sulfate proteoglycans regulate developmental signaling pathways (e.g., Wnt/BMP) and neurodegenerative processes. Recent studies include rescuing neurodegeneration in Drosophila models of Parkinson’s by modulating heparan sulfate function, linking lysosomal storage diseases (e.g., MPS) to age-related neurodegeneration via autophagy mechanisms. Awards: Phi Beta Kappa (1979) NIH Medical Scientist Training Program Fellowship (1981–1988) Alfred P. Sloan Foundation Fellowship (1994–1996) Advising & Grants: Long-term focus on mentoring trainees and securing funding for studies on neurological disorders. His lab investigates molecular mechanisms underlying mitochondrial dysfunction in neurodegeneration and environmental influences in autism. Labs/Teams: Leads a research group studying heparan sulfate biology and its implications for human diseases, with collaborations in developmental genetics and translational neuroscience.
Anna Majewska, Ph.D., is a Professor in the Department of Neuroscience at the University of Rochester School of Medicine and Dentistry (SMD), affiliated with the Del Monte Institute for Neuroscience and multiple interdisciplinary programs. Her research focuses on synaptic plasticity, microglial dynamics, and neurodegenerative diseases, particularly Alzheimer’s pathology. She holds the Dean’s Professorship and has appointments in multiple departments, including Neurobiology and Anatomy and the Center for Visual Science. Education: B.S. and M.S. in Biology/Chemistry, Stanford University (1992–1996) Ph.D. in Neurobiology and Behavior, Columbia University (1996–2001) Postdoctoral Fellowship, MIT Department of Brain and Cognitive Sciences (2000–2005) Research Interests: Dr. Majewska’s lab investigates synaptic structure-function relationships, microglial roles in neural circuits, and mechanisms underlying Alzheimer’s disease. Her work combines advanced imaging techniques (e.g., two-photon microscopy) with molecular and behavioral approaches to study how microglia interact with synapses during health and disease. Key projects include: Microglial regulation of synaptic plasticity in visual cortex Impact of neuroinflammation on Alzheimer’s pathology Neuroimmune interactions in developmental disorders Recent Articles: Her recent work emphasizes microglial signaling pathways in Alzheimer’s, P2Y12 receptor function in CNS dynamics, and sex-specific microglial responses. These studies bridge basic science and translational research, targeting therapeutic strategies for neurodegenerative diseases. Awards: Kavli Fellow (National Academy of Sciences, 2008) Cajal Club Cortical Explorer Award (2006) Burroughs-Wellcome Fund Career Development Award (2003–2008) Young Scientist Award (Polish Neuroscience Society, 2003) Advising & Grants: Dr. Majewska mentors postdoctoral associates (e.g., MaKenna Cealie, Mark Stoessel) and graduate students (e.g., Linh Le, Elizabeth Plunk). Her lab receives NIH T32 training grants and collaborates with institutions like the Environmental Health Sciences Center and the Neurobiology & Anatomy Ph.D. Program. Labs/Teams: The Majewska Lab is located at the URMC, focusing on cutting-edge imaging techniques and collaborative projects in neuroimmunology and synaptic biology.
Valdemar Grill is Senior Professor at NTNU's Department of Public Health and Nursing and HUNT Research Centre. His research focuses on diabetes pathophysiology, particularly autoimmune diabetes (LADA), metabolic regulation, and mitochondrial dysfunction in beta cells. Current investigations examine genetic and environmental determinants of diabetes progression, appetite hormone interactions, and mitochondrial responses to metabolic stressors. Clinical studies include trials of GAD-alum immunotherapy for LADA.
Marco Corazzari is an Associate Professor in the Department of Health Sciences at Università degli Studi del Piemonte Orientale. His research focuses on cellular stress responses, particularly endoplasmic reticulum (ER) stress, autophagy, and ferroptosis, with applications to cancer biology, neurodegenerative diseases, and gastrointestinal disorders. He leads projects on cancer cell survival mechanisms under stress, multiple sclerosis treatment implications, and pediatric obesity complications. Research interests include ER stress signaling, apoptosis regulation, and therapeutic strategies targeting ferroptosis. Recent work explores gliadin-induced pathology in celiac disease, gut microbiota dynamics in Alzheimer’s models, and drug delivery systems for doxorubicin. His studies bridge basic mechanisms with translational applications in oncology and metabolic disorders. Key Projects: Dissecting mutant p53’s role in cancer cell survival under stress ARC protein’s role in ferroptosis and multiple sclerosis Pediatric obesity and cardiovascular dysfunction markers Collaborative efforts span Italy and involve institutions like the MIUR and MUR. Publications emphasize cell death mechanisms, drug resistance, and biomarker discovery, with a focus on translational outcomes.
Ciro ISIDORO is a Full Professor at the Department of Health Sciences, University of Eastern Piedmont 'Amedeo Avogadro'. His research focuses on cancer biology, particularly autophagy mechanisms in ovarian cancer, lysosomal biology, and the therapeutic potential of natural compounds like resveratrol. He leads projects funded by institutions including the Regione Piemonte, MIUR, and the European Commission, investigating topics such as 3D organoid models, probiotic metabolites, and nanotheranostics. Key projects include: BANP: DA COMPILARE (2013-2016, European Commission) In vitro 3D organoid modeling of colon carcinoma (2017-2021, Università Piemonte Orientale) FFABR 2017- Fondo di finanziamento per le attività base di ricerca (2018-2021, MIUR) Rigenerazione tissutale ossea da cellule staminali gengivali (2017-2019, Università Piemonte Orientale) Research interests span autophagy regulation, tumor microenvironment dynamics, and epigenetic control by non-coding RNAs. He has published over 200 articles, with recent work emphasizing interdisciplinary approaches to cancer metabolism, drug delivery systems, and translational oncology. Collaborations include studies on neurodegenerative disorders, inflammatory bowel disease, and SARS-CoV-2 pathogenesis.
Zhigui Li is an Associate Research Scientist in the Department of Nephrology at Yale School of Medicine, Yale University. His work focuses on molecular mechanisms underlying kidney diseases, particularly podocyte biology, autophagy regulation, and oxidative stress responses. He holds a PhD from Nankai University and a BS from Guangxi University. Research Interests: Dr. Li's research explores the interplay between miRNA regulation, autophagy pathways, and kidney dysfunction. Key areas include: Nephrology: Kidney disease pathogenesis and therapeutic targets Podocyte Differentiation: miRNA-driven developmental mechanisms Oxidative Stress: Role in cellular injury and neuroprotection Autophagy: Protective roles in diabetes, neurodegeneration, and toxicant exposure His studies employ mouse models, cell culture systems, and integrated genomic analyses to dissect disease mechanisms. Publications: His recent work addresses topics like Polycystin-1 dosage effects in kidney disease (2023 JASN), miR-200's role in podocyte maturation (2016 Scientific Reports), and autophagy's neuroprotective role in diabetes (2016 BBR). These studies highlight his multidisciplinary approach bridging nephrology, cell biology, and molecular medicine.
Dr. Mark Mamula is a Professor of Medicine (Rheumatology) at Yale School of Medicine, part of Yale University. He focuses on autoimmune disease mechanisms, particularly in systemic lupus erythematosus (SLE) and type 1 diabetes. His research explores how post-translational protein modifications disrupt immune tolerance, leading to autoimmunity. Notably, his lab identified key roles for B cells in antigen presentation and epitope spreading in lupus. Dr. Mamula is also investigating therapeutic applications of these findings, including anti-tumor vaccines in breast and colon cancers. Education: PhD (University of Oklahoma, 1986), MS (University of Notre Dame, 1982), BA (University of California, Los Angeles, 1979). Research Interests: Autoantigen processing, T cell signaling, protein isoaspartyl modifications, β-cell stress in diabetes, and cancer immunology. Publications reflect a focus on molecular mechanisms in autoimmunity and translational medicine, with recent work on biomarkers (e.g., PDIA1 in diabetes) and therapeutic inhibitors targeting antigen presentation pathways. His phased retirement status suggests continued research engagement. Labs/Teams: Laboratory of Autoimmunity and Immunology at Yale School of Medicine, collaborating with cancer immunology and diabetes research groups.
Yumei Wu, PhD, is a Research Scientist in the Department of Neuroscience at the Yale School of Medicine, Yale University. She holds a PhD from Okayama University (2007). Her research focuses on synaptic vesicle biogenesis, endocytic pathways, and mechanisms underlying neurodegenerative diseases like Parkinson’s. Key contributions include elucidating roles of proteins such as synaptophysin, ATG9A, and VPS13B in synaptic and cellular processes. Collaborations include work with Pietro De Camilli, Hanieh Falahati, and Berrak Ugur on topics such as spine apparatus formation and Golgi cisternal dynamics. Her studies employ advanced techniques like FIB-SEM 3D imaging and proximity proteomics to explore membrane structures and protein interactions. Recent publications highlight synergistic effects of Parkinsonism-linked mutations on dopaminergic axons and the role of synapsin condensates in vesicle organization. Research spans cellular mechanisms in neurons, lipid transport, and autophagy, with implications for understanding neurodegenerative disorders.
